top of page
bednarczyk-M.jpg
Edward M. Bednarczyk PharmD, FCCP, FAPhA

Pharmaceutical & Regulatory Advisor

OptiMed Technology, INC. Buffalo NY

Director, Center for Health Outcomes, Pharmacoinformatics and Epidemiology

Chair, Clinical Associate Professor, Department of Pharmacy Practice, University at Buffalo

Edward M. Bednarczyk PharmD, FCCP, FAPhA

Professional Summary:

Dr. Bednarczyk’s research interests are focused to the application of molecular imaging techniques such as positron emission tomography (PET) to assessing drug effects, including the study of migraine headache where we have looked at treatment as well as induction of headache. We have also had recent work looking at opiate receptors in the human brain using 11C-carfentanil, a radiopharmaceutical that binds to the mu opiate receptor.

Dr. Bednarczyk's research had included a study on the regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine.

 

The characteristics of positron emitting radio nuclides often make them ideal tracers for measuring drug effects. This includes the labeling drugs with PET radio nuclides such as C-11, or F-18. These nuclides allow for creation of labeled drugs nearly identical to their unlabelled counterparts. We have also used ³workhorse¹ radiopharmaceuticals such as FDG in a variety of settings ranging from measuring the uptake of glucose into white blood cells, to oral administration of this radiopharmaceutical, to application in the assessment of response to drugs in dementia. Other research areas include migraine headache, and neuroreceptor binding studies.

Education and Training:

  • Cardiovascular Clinical Pharmacology Research, University Hospitals of Cleveland/Case Western Reserve University (1989)

  • PharmD, Pharmacy, Medical University of South Carolina, College of Pharmacy (1987)

  • Buffalo General Hospital (1985)

  • BS, The State University of New York at Buffalo, School of Pharmacy (1984)

 

Professional Memberships:

  • American Association of Colleges of Pharmacy (2008–present)

  • Society for Nuclear Medicine, Eastern Great Lakes Chapter SNM (1995–present)

  • American Headache Society (1995–present)

  • American Society for Clinical Pharmacology and Therapeutics (1987–2014)

  • Society for Nuclear Medicine (1987)

  • American College of Clinical Pharmacy (1985–present)

  • American Society of Health System Pharmacists (1985)

  • American Pharmacists Association (1984–present)

  • Christian Pharmacists Fellowship International

  • National Headache Foundation

  • New York State Chapter of the American College of Clinical Pharmacy

  • Society of Nuclear Imaging in Drug Development

  • Academy for Molecular Imaging (Society of Nuclear Imaging in Drug Development)

  • International Headache Society

  • American Heart Association

  • American Medical Writers Association

Journal Articles:

bottom of page